AHB
PRTK

Abner Herrman & Brock’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Abner Herrman & Brock’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,667
Closed -$40K – 103
2014
Q3 		$40K Hold
1,667
– – 0.01% 110
2014
Q2 		$40K Hold
1,667
– – 0.01% 109
2014
Q1 		$62K Hold
1,667
– – 0.02% 109
2013
Q4 		$68K Hold
1,667
– – 0.02% 91
2013
Q3 		$64K Hold
1,667
– – 0.04% 87
2013
Q2 		$60K Buy
+1,667
New +$71.4K 0.03% 85

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Abner Herrman & Brock's PRTK Position: Q4 2014 in Review

Abner Herrman & Brock sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2014, closing a stake of 1,667 shares — an estimated $40K sold.

Abner Herrman & Brock first reported a position in PRTK in Q2 2013 and held it in 6 quarters. The position peaked at $68K in Q4 2013. 37 funds tracked by Wall St. Rank hold PRTK as of Q4 2014.

  • Abner Herrman & Brock reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Abner Herrman & Brock sold 1,667 Paratek Pharmaceuticals, Inc. shares in Q4 2014, an estimated $40K.
  • Abner Herrman & Brock first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 6 quarters.
  • Abner Herrman & Brock's Paratek Pharmaceuticals, Inc. position peaked at $68K in Q4 2013.
  • 37 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2014.

Based on Abner Herrman & Brock's 13F filing for Q4 2014, filed 7 Jan 2015.